Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupivacaine SPG Block for Acute Headache
NCT05707754Phase 1Completed
- Sponsor
- Montefiore Medical Center
- Start
- Mar 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of bupivacaine in Headache (4 arms), sponsored by Montefiore Medical Center. Primary endpoint: Number of participants demonstrating sustained headache relief at 48 hours. Started Mar 2023; status: completed.
02
Drugs
bupivacaine
03
Conditions
Headache
Beyond the preview
Go deeper on NCT05707754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05707754.